CICON23 opened in Milan

The Seventh International Cancer Immunotherapy Conference CICON opened today in Milan with over 1,000 participants from 36 nations. From September 20-23, CICON23 is covering the latest advances in cancer immunology and immunotherapy.  

The conference will feature more than 50 lectures and over 600 posters covering the full range of research areas. 

The opening ENCI-AIRC lecture of CICON23 was given by by Nobel laureate Jim Allison, University of Texas MD Anderson Cancer Center, on “Immune Checkpoint Blockade in Cancer Therapy: historical perspective, new opportunities, and prospects for cures“. Other conference highlights will include the William B. Coley lecture presented by Tak Mak, University of Toronto. Prof. Mak will be introduced by Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs of the Cancer Research Institute. 

Alberto Mantovani, Humanitas Research Institute, will deliver the Pezcoller Lecture, on “Innate Immunity, Inflammation and Cancer: double edged swords”. On the last day of the conference, the AACR Keynote Lecture will present Toni Ribas, UCLA, who will speak about PD-1 blocckade immunotherapy for melanoma.

CIOCN23 is jointly presented by AACR, ENCI, and CRI.

CIMT is a founding member and partner of the European Network for Cancer Immunotherapy ENCI which harmonizes the activities of the European cancer immunotherapy community and fosters collaboration across organizations and countries. By providing and disseminating information, organizing scientific meetings and educating political decision makers, ENCI aims to advance the research and implementation of cancer immunotherapy in Europe.